Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 1/2016

01-03-2016

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)

Authors: Marina Nati, David Haddad, Andreas L. Birkenfeld, Christian A. Koch, Triantafyllos Chavakis, Antonios Chatzigeorgiou

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2016

Login to get access

Abstract

The low grade inflammatory state present in obesity promotes the progression of Non-Alcoholic Fatty Liver Disease (NAFLD). In Non-Alcoholic Steatohepatitis (NASH), augmented hepatic steatosis is accompanied by aberrant intrahepatic inflammation and exacerbated hepatocellular injury. NASH is an important disorder and can lead to fibrosis, cirrhosis and even neoplasia. The pathology of NASH involves a complex network of mechanisms, including increased infiltration of different subsets of immune cells, such as monocytes, T-lymphocytes and neutrophils, to the liver, as well as activation and in situ expansion of liver resident cells such as Kupffer cells or stellate cells. In this review, we summarize recent advances regarding understanding the role of the various cells of the innate and adaptive immunity in NASH development and progression, and discuss possible future therapeutic options and tools to interfere with disease progression.
Literature
1.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–112.PubMedCrossRef
2.
Berlanga A, Guiu-Jurado E. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7(1):221–39.PubMedPubMedCentral
3.
Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969–74.PubMedCrossRef
4.
Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.PubMedPubMedCentral
5.
Tang T, Sui Y, Lian M, Li Z, Hua J. Pro-inflammatory activated kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PLoS ONE. 2013;8(12):e81949.PubMedPubMedCentralCrossRef
6.
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10(4):355–61.PubMedCrossRef
7.
Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8.PubMedCrossRef
8.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterol. 2012;142(4):711–725.e6.
9.
Thörne A, Löfgren P, Hoffstedt J. Increased visceral adipocyte lipolysis–a pathogenic role in nonalcoholic fatty liver disease? J Clin Endocrinol Metab. 2010;95(10):E209–13.PubMedCrossRef
10.
Tilg H, Moschen A. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.PubMedCrossRef
11.
Luo Y, Burrington CM, Graff EC, et al. Metabolic phenotype and adipose and liver features in the high fat western diet-induced mouse model of obesity-linked NAFLD. Am J Physiol Endocrinol Metab 2015. doi:10.​1152/​ajpendo.​00319.
12.
Ge CX, Yu R, Xu MX, et al. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Eur J Pharmacol. 2016;770:154–64.
13.
Yimin, Furumaki H, Matsuoka S, et al. A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. Lab Investig. 2012;92(2):265–81.
14.
Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72–81.PubMedCrossRef
15.
16.
Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S–5S.PubMed
17.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29(1):415–45.PubMedCrossRef
18.
Phieler J, Chung K-J, Chatzigeorgiou A, et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. 2013;191(8):4367–74.PubMedCrossRef
19.
Chatzigeorgiou  A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia. 2012;55(10):2583–92.
20.
21.
Garcia-Martin R, Alexaki VI, Qin N, et al. Adipocyte-Specific Hif2α Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Mol Cell Biol. 2015;36(3):376–93.
22.
McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2015;41(1):36–48.CrossRef
23.
24.
Mehal W The inflammasome in liver injury and non-alcoholic Fatty liver disease. Dig Dis. 2013;(Il):507–15.
25.
Liang W, Lindeman JH, Menke AL, et al. Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation. Lab Investig. 2014;94(5):491–502.PubMedCrossRef
26.
Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47(3):215–25.PubMedCrossRef
27.
Marra F, Tacke F. Roles for Chemokines in Liver Disease. Gastroenterology. 2014;147(3):577–594.e1.
28.
Scapini P, Lapinet-Vera JA, Gasperini S, et al. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177(1):195–203.PubMedCrossRef
29.
Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Investig. 2000;80(5):617–53.PubMedCrossRef
30.
Nathan C Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173–82.PubMedCrossRef
31.
Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59(4):1393–405.PubMedCrossRef
32.
Alkhouri N, Morris-Stiff G, Campbell C, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32(2):297–302.PubMedCrossRef
33.
34.
Rensen SS, Slaats Y, Nijhuis J, et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009;175(4):1473–82.PubMedPubMedCentralCrossRef
35.
Pulli B, Ali M, Iwamoto Y, et al. Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. Antioxid Redox Signal. 2015;23(16):1255–69.
36.
Rensen SS, Bieghs V, Xanthoulea S, et al. Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS ONE. 2012;7(12):e52411.PubMedPubMedCentralCrossRef
37.
Hazen SL, Zhang R, Shen Z, et al. Formation of nitric oxide – derived oxidants by myeloperoxidase in monocytes. Circ Res. 1999;85:950–9.PubMedCrossRef
38.
Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10(7):1199–234.PubMedCrossRef
39.
Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-functional alteration or just a biomarker? Free Radic Biol Med. 2008;45(4):357–66.PubMedCrossRef
40.
Schults MA, Nagle PW, Rensen SS, et al. Decreased nucleotide excision repair in steatotic livers associates with myeloperoxidase-immunoreactivity. Mutat Res. 2012;736(1–2):75–81.PubMedCrossRef
41.
Talukdar S, Oh DY, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2013;18(9):1407–12.CrossRef
42.
Mansuy-Aubert V, Zhou QL, Xie X, et al. Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab. 2013;17(4):534–48.PubMedPubMedCentralCrossRef
43.
Syeda F, Tullis E, Slutsky AS, Zhang H. Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress. Am J Physiol Heart Circ Physiol. 2008;294(6):H2769–74.PubMedCrossRef
44.
Porro G. A, Lee JH, de Azavedo J, et al. Direct and indirect bacterial killing functions of neutrophil defensins in lung explants. Am J Physiol Lung Cell Mol Physiol. 2001;281(5):L1240–7.PubMed
45.
Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol. 2000;68(1):9–14.PubMed
46.
Ibusuki R, Uto H, Arima S, et al. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Liver Int. 2013;33(10):1549–56.PubMed
47.
Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1(3):199–205.PubMedCrossRef
48.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52.PubMedCrossRef
49.
O’Keeffe M, Hochrein H, Vremec D, et al. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8+ dendritic cells only after microbial stimulus. J Exp Med. 2002;196(10):1307–19.PubMedPubMedCentralCrossRef
50.
Helft J, Ginhoux F, Bogunovic M, Merad M. Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev. 2010;234(1):55–75.PubMedCrossRef
51.
Henning JR, Graffeo CS, Rehman A, et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013;58(2):589–602.PubMedPubMedCentralCrossRef
52.
Connolly M, Bedrosian A. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-α. J Clin Invest. 2009;119(11):3213–25.PubMedPubMedCentral
53.
Miyake T, Akbar SM, Yoshida O, et al. Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease. J Gastroenterol. 2010;45(8):859–67.PubMedCrossRef
54.
Ibrahim J, Nguyen AH, Rehman A, et al. Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver. Gastroenterology. 2013;143(4):1061–72.CrossRef
55.
Jiao J, Sastre D, Fiel MI, et al. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology. 2012;55(1):244–55.PubMedPubMedCentralCrossRef
56.
Bertola A, Ciucci T, Rousseau D, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes. 2012;61(9):2238–47.PubMedPubMedCentralCrossRef
57.
Tang Y, Bian Z, Zhao L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol. 2011;166(2):281–90.PubMedPubMedCentralCrossRef
58.
Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196(1):97–105.PubMedCrossRef
59.
Harley IT, Stankiewicz TE, Giles DA, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology. 2014;59(5):1830–9.PubMedPubMedCentralCrossRef
60.
Ju C, Pohl LR. Tolerogenic role of kupffer cells in immune-mediated adverse drug reactions. Toxicology. 2005;209(2):109–12.PubMedCrossRef
61.
Macchiarelli G, Motta PM, Fujita T. Scanning electron microscopy of the liver cells. Biopathology of the Liver. 1988:37–57.
62.
Stienstra R, Saudale F, Duval C, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology. 2010;51(2):511–22.PubMedCrossRef
63.
De Taeye BM, Novitskaya T, McGuinness OP, et al. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab. 2007;293(3):E713–25.PubMedCrossRef
64.
65.
Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Piña E, Geller DA. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res. 2008;147(1):153–9.PubMedPubMedCentralCrossRef
66.
Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59:347–57.PubMedPubMedCentralCrossRef
67.
Lanthier N, Molendi-Coste O, Cani PD, et al. Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. Faseb J. 2011;25(12):4301–11.PubMedCrossRef
68.
Lanthier N, Molendi-Coste O, Horsmans Y, et al. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298(1):G107–16.PubMedCrossRef
69.
Klein I, Cornejo JC, Polakos NK, et al. Kupffer cell heterogeneity : functional properties of bone marrow – derived and sessile hepatic macrophages. Blood. 2007;110(12):4077–85.
70.
Obstfeld AE, Sugaru E, Thearle M, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010;59(4):916–25.PubMedPubMedCentralCrossRef
71.
Egan CE, Daugherity EK, Rogers AB, et al. CCR2 and CD44 promote inflammatory cell recruitment during fatty liver formation in a lithogenic diet fed mouse model. PLoS ONE. 2013;8(6):e65247.PubMedPubMedCentralCrossRef
72.
Tacke F Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair. 2012;5:S27.PubMedPubMedCentralCrossRef
73.
Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302(11):G1310–21.PubMedPubMedCentralCrossRef
74.
Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287(48):40161–72.PubMedPubMedCentralCrossRef
75.
Kudo H, Yata Y, Takahara T, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 2009;29(7):988–96.PubMedCrossRef
76.
Nakashima H, Ogawa Y, Shono S, et al. Activation of CD11b + kupffer cells/macrophages as a common cause for exacerbation of TNF/Fas-ligand-dependent hepatitis in hypercholesterolemic mice. PLoS ONE. 2013;8(1):e49339.PubMedPubMedCentralCrossRef
77.
Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437–43.PubMedCrossRef
78.
Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38(5):1188–98.PubMedCrossRef
79.
Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59(2):347–57.PubMedPubMedCentralCrossRef
80.
81.
Olteanu S, Kandel-Kfir M, Shaish A, et al. Lack of interleukin-1α in kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice. Dig Liver Dis. 2014;46(5):433–9.PubMedCrossRef
82.
Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277(51):49982–8.PubMedCrossRef
83.
Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105(8):1095–108.
84.
Bieghs V, Verheyen F, van Gorp PJ, et al. Internalization of modified lipids by CD36 and SR-a leads to hepatic inflammation and lysosomal cholesterol storage in kupffer cells. PLoS ONE. 2012;7(3):1–7.CrossRef
85.
Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58(4):801–10.PubMedCrossRef
86.
Bieghs V, Walenbergh SM, Hendrikx T, van Gorp PJ, et al. Trapping of oxidized LDL in lysosomes of kupffer cells is a trigger for hepatic inflammation. Liver Int. 2013;33(7):1056–61.
87.
Bieghs V, Wouters K, van Gorp PJ, et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology. 2010;138(7):2477–86, 2486.e1–3.PubMedPubMedCentralCrossRef
88.
Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012;57(1):141–9.PubMedCrossRef
89.
Hendrikx T, Bieghs V, Walenbergh SM, et al. Macrophage specific caspase-1/11 deficiency protects against cholesterol crystallization and hepatic inflammation in hyperlipidemic mice. PLoS ONE. 2013;8(12):e78792.
90.
Ioannou GN, Van Rooyen DM, Savard C, et al. Cholesterol-Lowering drugs Cause Dissolution of Cholesterol Crystals and Disperse Kupffer Cell Crown-Like Structures During Resolution of NASH. J Lipid Res. 2015;56:277–85.
91.
Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology. 2009;50(2):612–21.PubMedPubMedCentralCrossRef
92.
Papackova Z, Palenickova E, Dankova H, et al. Kupffer cells ameliorate hepatic insulin resistance induced by high-fat diet rich in monounsaturated fatty acids : the evidence for the involvement of alternatively activated macrophages. Nutr Metab (Lond). 2012;9(1):1–15.CrossRef
93.
Schmitt N, Ueno H. Regulation of human helper T cell subset differentiation by cytokines. Curr Opin Immunol. 2015;34:130–6.PubMedCrossRef
94.
95.
Lieberman J Anatomy of a murder: how cytotoxic T cells and NK cells are activated, develop, and eliminate their targets. Immunol Rev. 2010;235(1):5–9.PubMedCrossRef
96.
Inzaugarat ME, Ferreyra Solari NE, Billordo LA, et al. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J Clin Immunol. 2011;31(6):1120–30.PubMedCrossRef
97.
Ljunggren H-G, Glas R, Sandberg JK, Kärre K. Reactivity and specificity of CD8+ T cells in mice with defects in the MHC class I antigen-presenting pathway. Immunol Rev. 1996;151(1):123–48.PubMedCrossRef
98.
Arindkar S, Bhattacharjee J, Kumar JM, et al. Antigen peptide transporter 1 is involved in the development of fructose-induced hepatic steatosis in mice. J Gastroenterol Hepatol. 2013;28(8):1403–9.PubMedCrossRef
99.
Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol. 2007;19(6):353–61.PubMedCrossRef
100.
Tan Z, Qian X, Jiang R, et al. IL-17 a plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013;191(4):1835–44.PubMedCrossRef
101.
Du WJ, Zhen JH, Zeng Z-Q, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013;8(1):40.PubMedPubMedCentralCrossRef
102.
Meng F, Wang K, Aoyama T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143(3):765–76.e1–3.PubMedPubMedCentralCrossRef
103.
104.
Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64.PubMedCrossRef
105.
Wagner NM, Brandhorst G, Czepluch F, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity. 2013;21(3):461–8.PubMedCrossRef
106.
Cipolletta D Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology. 2014;142(4):517–25.PubMedPubMedCentralCrossRef
107.
Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9.PubMedPubMedCentralCrossRef
108.
Cipolletta D, Feuerer M, Li A, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue treg cells. Nature. 2012;486(7404):549–53.PubMedPubMedCentral
109.
Bapat SP, Myoung Suh J, Fang S, et al. Depletion of fat-resident treg cells prevents age-associated insulin resistance. Nature. 2015;528(7580):137–41.PubMedPubMedCentral
110.
Ma X, Hua J, Mohamood AR, et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology. 2007;46(5):1519–29.PubMedCrossRef
111.
Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12(4):431–40.
112.
Poggi M, Morin SO, Bastelica D, et al. CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. Int J Obes. 2015;39(6):977–85.CrossRef
113.
Chatzigeorgiou A, Chung K-J, Garcia-Martin R, et al. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology. 2014;60(4):1196–210.PubMedCrossRef
114.
Zhong J, Rao X, Braunstein Z, et al. T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance. Diabetes. 2014;63(4):1289–302.PubMedPubMedCentralCrossRef
115.
Chatzigeorgiou A, Seijkens T, Zarzycka B, et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci U S A. 2014;111(7):2686–91.PubMedPubMedCentralCrossRef
116.
Guo CA, Kogan S, Amano SU, et al. CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance. Am J Physiol Endocrinol Metab. 2013;304(9):E951–63.PubMedPubMedCentralCrossRef
117.
Wolf D, Jehle F, Michel NA, et al. Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice. Circulation. 2014;129(23):2414–25.PubMedCrossRef
118.
van den Berg SM, Seijkens TT, Kusters PJ, et al. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. Int J Obes. 2015;39(5):782–90.CrossRef
119.
Poggi M, Engel D, Christ A, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol. 2011;31(10):2251–60.PubMedCrossRef
120.
121.
Kremer M, Thomas E, Milton RJ, et al. Kupffer cell and interleukin-12 dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010;51(1):130–41.PubMedPubMedCentralCrossRef
122.
Wu L, Parekh VV, Gabriel CL, et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc Natl Acad Sci U S A. 2012;109(19):E1143–52.PubMedPubMedCentralCrossRef
123.
124.
Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011;53(1):106–15.PubMedPubMedCentralCrossRef
125.
126.
Carpino G, Renzi A, Onori P, Gaudio E. Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. Int J Mol Sci. 2013;14(10):20112–30.PubMedPubMedCentralCrossRef
127.
Blaner WS, O’Byrne SM, Wongsiriroj N, et al. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta. 2009;1791(6):467–73.PubMedPubMedCentralCrossRef
128.
Galli A, Crabb D, Price D, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology. 2000;31(1):101–8.PubMedCrossRef
129.
Tsukamoto H Adipogenic Phenotype of Hepatic Stellate Cells. Alcohol Clin Exp Res. 2005;29(Supplement):132S–3S.PubMedCrossRef
130.
Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119(2):466–78.PubMedCrossRef
131.
Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122(7):1924–40.PubMedCrossRef
132.
Enzan H, Himeno H, Iwamura S, et al. Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch. 1994;424(3):249–56.
133.
Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol. 2008;43(6):419–28.PubMedCrossRef
134.
Nieto N, Friedman S. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology. 1999;30(4):987–96.PubMedCrossRef
135.
Svegliati-Baroni G, Saccomanno S, Van Goor H, et al. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver. 2001;21(1):1–12.PubMedCrossRef
136.
Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGFa and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96(November):2461–8.PubMedPubMedCentralCrossRef
137.
Wheeler M The role of kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med. 2001;31(12):1544–9.PubMedCrossRef
138.
De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-β gene expression in normal and fibrotic rat liver. J Hepatol 1997;26(4):886–893.
139.
Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30(1):77–87.PubMedCrossRef
140.
Yang Y, Kim B, Park YK, Koo SI, Lee JY. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochim Biophys Acta - Gen Subj. 2015;1850(1):178–85.CrossRef
141.
Pradere JP, Kluwe J, De Minicis S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013;58(4):1461–73.PubMedCrossRef
142.
Oakley F, Meso M, Iredale JP, et al. Inhibition of inhibitor of κB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology. 2005;128(1):108–20.PubMedCrossRef
143.
144.
Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr. 2014;3(6):344–63.PubMedPubMedCentral
145.
Potter JJ, Rennie-tankesley L, Mezey E. Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration. J Hepatol. 2003;38(4):281–8.PubMedCrossRef
146.
Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36(2):403–9.PubMedCrossRef
147.
Otte C, Otte JM, Strodthoff D, et al. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes. 2004;112(1):10–7.PubMedCrossRef
148.
Ikejima K, Takei Y, Honda H, et al. Leptin receptor–mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122(5):1399–410.PubMedCrossRef
149.
150.
Choi SS, Syn WK, Karaca GF, et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem. 2010;285(47):36551–60.PubMedPubMedCentralCrossRef
151.
Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem. 2000;275(46):35715–22.PubMedCrossRef
152.
Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol. 2006;21(Suppl 3):S102–5.PubMedCrossRef
153.
154.
Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab. 2015;25(11):576–85.CrossRef
155.
156.
Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571–9.PubMedPubMedCentralCrossRef
157.
Perry RJ, Camporez JP, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745–58.PubMedPubMedCentralCrossRef
158.
Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29(7):939–60.PubMedCrossRef
159.
Wehr A, Baeck C, Ulmer F, et al. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. PLoS ONE. 2014;9(11):e112327.PubMedPubMedCentralCrossRef
160.
Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012;61(3):416–26.PubMedCrossRef
161.
Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016;64(1):160–70.
162.
Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014;61(6):1365–75.PubMedCrossRef
163.
Deng YR, Ma HD, Tsuneyama K, et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun. 2013;46:25–34.PubMedCrossRef
164.
Beraza N, Malato Y, Vander Borght S, et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut. 2008;57(5):655–63.PubMedCrossRef
165.
Zhou Z, Liu Y, Chen X, Li F, Tong X, Ding Y, Tang C. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice. Mol Med Rep. 2015;12(5):6925–31.
Metadata
Title
The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)
Authors
Marina Nati
David Haddad
Andreas L. Birkenfeld
Christian A. Koch
Triantafyllos Chavakis
Antonios Chatzigeorgiou
Publication date
01-03-2016
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 1/2016
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9339-2

Other articles of this Issue 1/2016

Reviews in Endocrine and Metabolic Disorders 1/2016 Go to the issue

ReviewPaper

Determinants of mortality in patients with type 2 diabetes: a review

ReviewPaper

The metabolic vascular syndrome - guide to an individualized treatment

ReviewPaper

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy

ReviewPaper

The role of innate immunity in the regulation of brown and beige adipogenesis

EditorialNotes

Introduction to Hanefeld Symposium: 40+ years of metabolic syndrome

ReviewPaper

Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits